Secondary Progressive Multiple Sclerosis (SPMS) - A Detailed Overview

  • ID: 4431984
  • Report
  • Region: Global
  • Pharma Scroll
1 of 3

This report provides an overview of secondary progressive multiple sclerosis (SPMS) disease indication in detail, highlights SPMS epidemiology in key geographies, elaborates on the drugs prescribed and expected to be prescribed in SPMS and covers the market in detail in terms of drugs and countries by sales value and patient numbers, in addition to forecasts. The report elaborates on the Secondary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of SPMS patients, symptoms of SPMS patients, and the disease progression in SPMS patients.

The report further highlights the multiple methods through which the patient can be diagnosed for SPMS. The next part of the report consists of SPMS epidemiology and prevalence in key geographies across the globe such as the US, the UK, Germany, Italy, France, Spain and Japan. The epidemiology for SPMS indication across key geographies has been forecasted to 2024. The next part of the report highlights the importance of factors influencing the physician prescription decisions in SPMS like efficacy factors, tolerability factors, monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in SPMS by the physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of the drug in the SPMS market. The report further details the drug attribute analysis on each parameter considered important in the prescription of SPMS drugs. The report also covers other products which are currently in the pipeline for SPMS and other progressive forms of MS. The final part of the report provides a detailed overview of the SPMS market sizing drug wise and geography wise both in terms of sales value and patient numbers. The drugs have been forecasted to 2030 both for sales value and patient numbers geography wise.

READ MORE
Note: Product cover images may vary from those shown
2 of 3

1. Multiple Sclerosis Definition

2. Types of Multiple Sclerosis

a. Relapsing Remitting MS

b. Secondary Progressive MS

c. Primary Progressive MS

d. Progressive Relapsing MS

3. Secondary Progressive Relapsing MS Defined

4. Causes of SPMS

5. Profile of SPMS Patient

6. Symptoms of SPMS

7. Disease progression and impact on QoL

8. Disease Diagnosis

a. Disease diagnosis through symptoms

b. Disease diagnosis through medical tests

9. Disease Epidemiology

a. US Epidemiology

b. UK Epidemiology

c. Germany Epidemiology

d. Italy Epidemiology

e. France Epidemiology

f. Spain Epidemiologyg. Japan Epidemiology

10. Factors impacting a physician’s prescription decision

a. Efficacy

b. Tolerability and Safety

c. Monitoring Requirements

d. Pricing and Reimbursement

11. Disease Modifying Therapies for SPMS

a. Laquinimod

i. About the Product

ii. Patent and Trial Details

iii. Impact of Laquinimod

b. Lemtrada

i. About the Product

ii. Patent and Trial Details

iii. Impact of Lemtrada

c. Masitinib

i. About the Product

ii. Patent and Trial Details

iii. Impact of Masitinib

d. Ocrelizumab

i. About the Product

ii. Patent and Trial Details

iii. Impact of Ocrelizumabe

e. Tysabri

i. About the Product

ii. Patent and Trial Details

iii. Impact of Tysabri

f. Siponimod

i. About the Product

ii. Patent and Trial Details

iii. Impact of Siponimod

g. Zinbryta

i. About the Product

ii. Patent and Trial Details

iii. Impact of Zinbryta

h. Mitoxantrone

i. About the Product

ii. Patent and Trial Details

iii. Impact of Mitoxantrone

i. Ponesimod

i. About the Product

ii. Patent and Trial Details

iii. Impact of Ponesimod

12. Drug Attribute Analysis

a. Laquinimod

b. Lemtrada

c. Masitinib

d. Ocrelizumab

e. Ponesimod

f. Siponimod

g. Tysabri

h. Zinbryta

i. Mitoxantrone

13. Other Pipeline Products

a. Number of Pipeline Products phase wise

b. Number of Companies having other pipeline products phase wise

14. SPMS Market Sizing

a. Laquinimod

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

b. Lemtrada

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

c. Masitinib

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

d. Ocrelizumab

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

e. Ponesimod

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

f. Siponimod

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

g. Tysabri

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

h. Zinbryta

i. Value sales in SPMS indication

ii. Patient numbers in SPMS indication

iii. Value sales by key geographies/countries

iv. Patient numbers by key geographies/countries

15.Market Sizing Country Wise

a. Global

i. Value sales by Brand

ii. Patient numbers by Brand

b. US

i. Value sales by Brand

ii. Patient numbers by Brand

c. Germany

i. Value sales by Brand

ii. Patient numbers by Brand

d. France

i. Value sales by Brand

ii. Patient numbers by Brand

e. Italy

i. Value sales by Brand

ii. Patient numbers by Brand

f. Spain

i. Value sales by Brand

ii. Patient numbers by Brand

g. UK

i. Value sales by Brand

ii. Patient numbers by Brand

h. Canada

i. Value sales by Brand

ii. Patient numbers by Brand

i. Australia

i. Value sales by Brand

ii. Patient numbers by Brand

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll